



## ASX AND MEDIA RELEASE

### Peplin to Participate in BayBio 2009

**EMERYVILLE, California and BRISBANE, Australia, 15 April 2009: Peplin, Inc.** (ASX:PLI) announced today that Janice Drew, Senior Director of Clinical Development, will participate in the BayBio 2009: Navigating the Storm Conference occurring in South San Francisco on Thursday, April 16, 2009. Ms. Drew, MPH, will share her extensive experience in clinical strategy and operations as a part of the Essentials of a Strategic Clinical Development Plan panel, which addresses the need to match development strategies with corporate business model.

**Further information:**

Tom Wiggans  
Chief Executive Officer  
Tel: +1-510-653 9700  
[tom.wiggans@peplin.com](mailto:tom.wiggans@peplin.com)

**ABOUT PEPLIN**

Peplin is a development stage specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. Peplin is currently developing PEP005 (ingenol mebutate), which is the first in a new class of compounds and which is derived from the sap of *Euphorbia peplus*, or *E. peplus*, a rapidly growing, readily available plant commonly referred to as petty spurge or radium weed. *E. peplus* has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, including skin cancer and pre-cancerous skin lesions. Peplin's lead product candidate is a patient-applied topical gel containing ingenol mebutate, a compound the use of which Peplin has patented for the treatment of actinic (solar) keratosis, or AK. This product candidate is currently in Phase III clinical trials (trial known as REGION-I) and is referred to as PEP005 (ingenol mebutate) Gel.

**PEPLIN, INC.**

6475 Christie Avenue, Emeryville, CA 94608, USA  
Tel: +1-510-653 9700 Fax: +1-510-653 9704

Level 2, Brisbane Portal, 1 Breakfast Creek Road, Newstead, QLD, 4006, Australia  
Tel: +61-7-3250 1200 Fax: +61-7-3250 1299